The stock of Endo International plc (NASDAQ:ENDP) closed at $6.53 gaining 3.57% in yesterday’s trading session. It was on Thursday that Endo International Plc made a statement outlining that it had obtained a preliminary injunction. It would thus be possible to bar the privately-held QuVa Pharma Inc from either releasing or marketing a compounded drug that could pose serious competition to Vasostrict which happens to be its rival its blood pressure shot.
The U.S. District Judge Brian Martinotti was the one that issued out the injunction and he did that in Trenton, New Jersey. It was an injunction directed at two subsidiaries of Endo which are at the moment launching claims that its compounded product in a major way misappropriates the various trade secrets in line with Vasostrict.
Bulk compounding has pretty much to do with how the various facilities are able to come up with doses of drugs for specific patients and it is a matter that is becoming rather widespread in the United States.
It was just recently when Endo moved ahead to separately file a lawsuit against the U.S. Food and Drug Administration (FDA) where it made claims that the agency had improperly authorized the bulk compounding of quite a significant number of drugs.
It reached a point when the board members of Endo decided to put a hold on the lawsuit and anytime soon it is expected that the FDA might be unleashing a new criteria. It is that criteria that will assist in making the determination on what particular substances to use in order to produce drugs in bulk. It will be a major step forward for the hospitals and to be more specific for the doctors’ offices and of course that will be happening without any individual patient prescriptions.
A person familiar with the matter opined, “A 2013 law permitted outsourcing facilities that could register with the FDA and sell compounded products in bulk without prescriptions for individual patients in accordance with federal manufacturing standards.”
A number of journalists moved out in a bid to get the lawyers of the company to make comments in relation to the most recent developments. They declined to comment.